This is consistent with studies that showed PARPi(s) in combination with platinum-based drugs provide benefit not only to patients with germline BRCA1/2 mutations but also for breast cancers having molecular characteristics of BRCA1/2 mutant tumors or BRCAness. The gene discussed is BRCA1; the disease is breast carcinoma.